Hospital
Usc Arcadia Hospital
Usc Arcadia Hospital was paid $11.65M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 0450, Emergency room services — 21% of everything it billed.
33Billing provider infoUSC ARCADIA HOSPITAL
ARCADIA, CA 91007
ARCADIA, CA 91007
33aNPI1508851288assigned 09/19/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.65M
24GClaims617,596
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#164 of 410
Median peer was paid$6.90M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 101,391 | $1.80M | |
| 2019 | 85,855 | $1.65M | |
| 2020 | 60,063 | $1.10M | |
| 2021 | 74,504 | $1.48M | |
| 2022 | 92,491 | $1.83M | |
| 2023 | 105,292 | $2.08M | |
| 2024incomplete | 98,000 | $1.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 21% | 64,646 | 58,560 | $2.48M |
| 70450 | Computed tomography, head or brain; without contrast material | 6.6% | 8,180 | 7,894 | $773K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 4,429 | 4,310 | $685K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.7% | 16,623 | 15,518 | $659K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.1% | 5,309 | 4,972 | $600K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.8% | 12,163 | 10,361 | $445K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.5% | 21,492 | 20,100 | $409K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.4% | 9,849 | 8,936 | $392K |
| 80053 | Comprehensive metabolic panel | 2.6% | 36,239 | 33,095 | $301K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.4% | 13,479 | 9,426 | $277K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 3,121 | 3,053 | $272K |
| 99199 | Unlisted special service, procedure or report | 2.1% | 8,502 | 7,779 | $244K |
170 more codes
| 71045 | Radiologic examination, chest; single view | 2.1% | 24,719 | $242K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 5,219 | $216K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 39,718 | $212K |
| Z7502 | 1.7% | 5,504 | $196K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 3,916 | $172K |
| 99283 | Emergency room visit (moderate) | 1.5% | 2,436 | $169K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.2% | 1,340 | $143K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 7,110 | $120K |
| 84484 | 1.0% | 15,459 | $118K | |
| J3490 | Unclassified drugs | <1% | 22,992 | $104K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,442 | $98K |
| 83880 | <1% | 5,308 | $97K | |
| 0270 | <1% | 17,489 | $87K | |
| 0250 | <1% | 15,857 | $83K | |
| 93971 | <1% | 1,179 | $83K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,049 | $77K |
| 83690 | <1% | 13,456 | $67K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,504 | $67K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 506 | $62K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,320 | $62K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,598 | $61K |
| 0300 | <1% | 1,538 | $59K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,851 | $57K |
| 86710 | <1% | 6,228 | $53K | |
| 84703 | <1% | 11,353 | $52K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,750 | $49K |
| 0762 | <1% | 554 | $49K | |
| 81001 | <1% | 18,700 | $43K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,316 | $41K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,336 | $40K |
| 99221 | <1% | 1,556 | $39K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,973 | $36K |
| 76801 | <1% | 949 | $36K | |
| 87088 | <1% | 6,789 | $36K | |
| 73564 | <1% | 1,670 | $34K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,924 | $34K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,651 | $34K |
| 0510 | <1% | 2,004 | $33K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 270 | $32K |
| 85610 | <1% | 9,863 | $32K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,040 | $30K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,893 | $30K |
| 73630 | <1% | 1,609 | $29K | |
| 87040 | <1% | 2,084 | $27K | |
| 83605 | <1% | 3,362 | $26K | |
| 90715 | <1% | 1,164 | $26K | |
| 73610 | <1% | 1,279 | $24K | |
| 72100 | <1% | 909 | $23K | |
| 0272 | <1% | 2,756 | $22K | |
| 87186 | <1% | 2,835 | $20K | |
| 73130 | <1% | 969 | $20K | |
| 86756 | <1% | 2,331 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,423 | $19K |
| 73030 | <1% | 1,110 | $19K | |
| 96376 | <1% | 1,809 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 901 | $15K |
| 84702 | <1% | 1,847 | $15K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 369 | $15K |
| 85379 | <1% | 2,060 | $14K | |
| G0378 | Hospital observation service, per hour | <1% | 130 | $13K |
| 72131 | <1% | 109 | $13K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 640 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,406 | $13K |
| 83735 | <1% | 2,834 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 257 | $12K |
| 82948 | <1% | 3,369 | $12K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,765 | $11K |
| 70496 | <1% | 75 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 782 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 832 | $9K |
| 0160 | <1% | 102 | $8K | |
| 86901 | <1% | 3,095 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,779 | $8K |
| 73110 | <1% | 411 | $8K | |
| 93970 | <1% | 66 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,682 | $7K |
| 85730 | <1% | 2,021 | $7K | |
| 86900 | <1% | 3,109 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 322 | $7K |
| 0636 | <1% | 1,539 | $6K | |
| 70498 | <1% | 74 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 444 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 899 | $6K |
| Z7610 | <1% | 573 | $6K | |
| 86886 | <1% | 1,297 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,750 | $6K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,863 | $6K |
| 99070 | <1% | 541 | $6K | |
| 81003 | <1% | 3,858 | $6K | |
| 70486 | <1% | 55 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 150 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,244 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 215 | $5K |
| 81002 | <1% | 3,261 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 215 | $5K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 135 | $5K |
| 0761 | <1% | 317 | $4K | |
| 99285 | Emergency room visit (most serious) | <1% | 31 | $4K |
| 0760 | <1% | 328 | $4K | |
| 86850 | <1% | 877 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 919 | $4K |
| 73080 | <1% | 155 | $3K | |
| 73502 | <1% | 143 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 69 | $3K |
| 80061 | Lipid panel | <1% | 464 | $3K |
| 87070 | <1% | 579 | $3K | |
| 86140 | <1% | 741 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 50 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 300 | $2K |
| 12001 | <1% | 39 | $2K | |
| 73590 | <1% | 150 | $2K | |
| 85651 | <1% | 969 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 112 | $2K |
| 0324 | <1% | 138 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 650 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 560 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 311 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 190 | $2K |
| 88312 | <1% | 251 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 193 | $2K |
| 74018 | <1% | 117 | $2K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 191 | $1K |
| 71101 | <1% | 53 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 154 | $1K |
| 29125 | <1% | 39 | $1K | |
| 82803 | <1% | 104 | $1K | |
| 0710 | <1% | 114 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 244 | $1K |
| 96367 | <1% | 38 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $968.72 |
| J1815 | Injection, insulin, per 5 units | <1% | 87 | $897.66 |
| 72040 | <1% | 40 | $882.28 | |
| 59899 | <1% | 78 | $813.99 | |
| 71010 | <1% | 55 | $807.78 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 56 | $760.87 |
| 73140 | <1% | 57 | $648.33 | |
| 76870 | <1% | 24 | $647.88 | |
| A4649 | Surgical supply; miscellaneous | <1% | 679 | $640.34 |
| 82728 | <1% | 56 | $591.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 121 | $570.30 |
| 99499 | <1% | 13 | $545.60 | |
| 82550 | <1% | 122 | $531.77 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 355 | $530.26 |
| 81025 | <1% | 146 | $511.59 | |
| 83615 | <1% | 77 | $490.05 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 42 | $383.39 |
| 12011 | <1% | 12 | $294.16 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 142 | $270.37 |
| 80076 | <1% | 41 | $248.11 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 18 | $225.23 |
| 87205 | <1% | 60 | $212.72 | |
| 73090 | <1% | 13 | $172.84 | |
| 87210 | <1% | 64 | $148.07 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 41 | $135.52 |
| S0028 | Injection, famotidine, 20 mg | <1% | 103 | $112.27 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 13 | $111.58 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 15 | $95.32 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 30 | $80.07 |
| 82140 | <1% | 13 | $75.73 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 27 | $65.20 |
| 59025 | Fetal non-stress test | <1% | 14 | $61.34 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $54.27 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 15 | $51.77 |
| 84100 | <1% | 15 | $49.19 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $39.71 |
| 29515 | <1% | 13 | $36.00 | |
| 84460 | <1% | 15 | $16.96 | |
| 80354 | 0% | 16 | $0.00 | |
| 0730 | 0% | 13 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 187 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMMEJE, IKENNA (PRESIDENT, CEO)